102 related articles for article (PubMed ID: 24166743)
1. Suitability of digoxin as a P-glycoprotein probe: implications of other transporters on sensitivity and specificity.
Nader AM; Foster DR
J Clin Pharmacol; 2014 Jan; 54(1):3-13. PubMed ID: 24166743
[TBL] [Abstract][Full Text] [Related]
2. Quantitative investigation of the impact of P-glycoprotein inhibition on drug transport across blood-brain barrier in rats.
Sugimoto H; Hirabayashi H; Kimura Y; Furuta A; Amano N; Moriwaki T
Drug Metab Dispos; 2011 Jan; 39(1):8-14. PubMed ID: 20962062
[TBL] [Abstract][Full Text] [Related]
3. Refining the in vitro and in vivo critical parameters for P-glycoprotein, [I]/IC50 and [I2]/IC50, that allow for the exclusion of drug candidates from clinical digoxin interaction studies.
Cook JA; Feng B; Fenner KS; Kempshall S; Liu R; Rotter C; Smith DA; Troutman MD; Ullah M; Lee CA
Mol Pharm; 2010 Apr; 7(2):398-411. PubMed ID: 20025245
[TBL] [Abstract][Full Text] [Related]
4. P-glycoprotein related drug interactions: clinical importance and a consideration of disease states.
Lee CA; Cook JA; Reyner EL; Smith DA
Expert Opin Drug Metab Toxicol; 2010 May; 6(5):603-19. PubMed ID: 20397967
[TBL] [Abstract][Full Text] [Related]
5. Kinetic identification of membrane transporters that assist P-glycoprotein-mediated transport of digoxin and loperamide through a confluent monolayer of MDCKII-hMDR1 cells.
Acharya P; O'Connor MP; Polli JW; Ayrton A; Ellens H; Bentz J
Drug Metab Dispos; 2008 Feb; 36(2):452-60. PubMed ID: 17967933
[TBL] [Abstract][Full Text] [Related]
6. Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug.
Fenner KS; Troutman MD; Kempshall S; Cook JA; Ware JA; Smith DA; Lee CA
Clin Pharmacol Ther; 2009 Feb; 85(2):173-81. PubMed ID: 18987624
[TBL] [Abstract][Full Text] [Related]
7. In vitro predictability of drug-drug interaction likelihood of P-glycoprotein-mediated efflux of dabigatran etexilate based on [I]2/IC50 threshold.
Kishimoto W; Ishiguro N; Ludwig-Schwellinger E; Ebner T; Schaefer O
Drug Metab Dispos; 2014 Feb; 42(2):257-63. PubMed ID: 24212378
[TBL] [Abstract][Full Text] [Related]
8. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity.
Taub ME; Podila L; Ely D; Almeida I
Drug Metab Dispos; 2005 Nov; 33(11):1679-87. PubMed ID: 16093365
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation.
Ma JD; Tsunoda SM; Bertino JS; Trivedi M; Beale KK; Nafziger AN
Clin Pharmacokinet; 2010 Apr; 49(4):223-37. PubMed ID: 20214407
[TBL] [Abstract][Full Text] [Related]
10. The utility of in vitro data in making accurate predictions of human P-glycoprotein-mediated drug-drug interactions: a case study for AZD5672.
Elsby R; Gillen M; Butters C; Imisson G; Sharma P; Smith V; Surry DD
Drug Metab Dispos; 2011 Feb; 39(2):275-82. PubMed ID: 21075975
[TBL] [Abstract][Full Text] [Related]
11. Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein.
Keogh JP; Kunta JR
Eur J Pharm Sci; 2006 Apr; 27(5):543-54. PubMed ID: 16406207
[TBL] [Abstract][Full Text] [Related]
12. A P-gp vesicular transport inhibition assay - optimization and validation for drug-drug interaction testing.
Herédi-Szabó K; Palm JE; Andersson TB; Pál Á; Méhn D; Fekete Z; Beéry E; Jakab KT; Jani M; Krajcsi P
Eur J Pharm Sci; 2013 Jul; 49(4):773-81. PubMed ID: 23684934
[TBL] [Abstract][Full Text] [Related]
13. ITC commentary on the prediction of digoxin clinical drug-drug interactions from in vitro transporter assays.
Lee CA; Kalvass JC; Galetin A; Zamek-Gliszczynski MJ
Clin Pharmacol Ther; 2014 Sep; 96(3):298-301. PubMed ID: 25141954
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of an unusual, but clinically significant, digoxin-bupropion drug interaction.
He J; Yu Y; Prasad B; Chen X; Unadkat JD
Biopharm Drug Dispos; 2014 Jul; 35(5):253-63. PubMed ID: 24436229
[TBL] [Abstract][Full Text] [Related]
15. Ultrafast mass spectrometry based bioanalytical method for digoxin supporting an in vitro P-glycoprotein (P-gp) inhibition screen.
Wagner AD; Kolb JM; Ozbal CC; Herbst JJ; Olah TV; Weller HN; Zvyaga TA; Shou WZ
Rapid Commun Mass Spectrom; 2011 May; 25(9):1231-40. PubMed ID: 21488121
[TBL] [Abstract][Full Text] [Related]
16. In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates.
Rautio J; Humphreys JE; Webster LO; Balakrishnan A; Keogh JP; Kunta JR; Serabjit-Singh CJ; Polli JW
Drug Metab Dispos; 2006 May; 34(5):786-92. PubMed ID: 16455806
[TBL] [Abstract][Full Text] [Related]
17. Utility of 96 well Caco-2 cell system for increased throughput of P-gp screening in drug discovery.
Balimane PV; Patel K; Marino A; Chong S
Eur J Pharm Biopharm; 2004 Jul; 58(1):99-105. PubMed ID: 15207543
[TBL] [Abstract][Full Text] [Related]
18. Transporters and drug therapy: implications for drug disposition and disease.
Ho RH; Kim RB
Clin Pharmacol Ther; 2005 Sep; 78(3):260-77. PubMed ID: 16153397
[TBL] [Abstract][Full Text] [Related]
19. In vivo probes of drug transport: commonly used probe drugs to assess function of intestinal P-glycoprotein (ABCB1) in humans.
Oswald S; Terhaag B; Siegmund W
Handb Exp Pharmacol; 2011; (201):403-47. PubMed ID: 21103977
[TBL] [Abstract][Full Text] [Related]
20. Establishment of in vitro P-glycoprotein inhibition assay and its exclusion criteria to assess the risk of drug-drug interaction at the drug discovery stage.
Sugimoto H; Matsumoto S; Tachibana M; Niwa S; Hirabayashi H; Amano N; Moriwaki T
J Pharm Sci; 2011 Sep; 100(9):4013-23. PubMed ID: 21678427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
